{"entity":{"id":"fmc-376","kind":"drug","name":"FMC-376","aka":[],"tldr":"FMC-376 is an experimental oral covalent small molecule from Frontier Medicines, in phase 1 trials for KRAS G12C-mutated solid tumours and non-small cell lung cancer.","summary":"FMC-376 is an oral covalent small molecule from Frontier Medicines. A dual inhibitor that targets both the active (GTP-bound, 'ON') and inactive (GDP-bound, 'OFF') forms of KRAS G12C. Its furthest stage is phase 1, for KRAS G12C-mutated solid tumours and non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 PROSPER NCT06244771 recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Frontier Medicines: frontiermeds.com","url":"https://www.frontiermeds.com/precision-pipeline/KRAS-GTP"},{"label":"Frontier Medicines: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06244771"},{"label":"ClinicalTrials.gov: trials of FMC-376","url":"https://clinicaltrials.gov/search?intr=FMC-376"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","nsclc"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["frontier-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06244771"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"FMC-376","modality":"Oral covalent small molecule","mechanism":"A dual inhibitor that targets both the active (GTP-bound, 'ON') and inactive (GDP-bound, 'OFF') forms of KRAS G12C.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fmc-376/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/"}],"trial":[{"id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","route":"/trials/nct06244771/"}]}}